Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.

ABSTRACT:

Background

Uterine fibroids are one of the most common neoplasms found among women globally, with a prevalence of approximately 11 million women in the United States alone. The morbidity of this common disease is significant because it is the leading cause of hysterectomy and causes significant functional impairment for women of reproductive age. Factors including age, body mass index, race, ethnicity, menstrual blood loss, fibroid location, and uterine and fibroid volume influence the incidence of fibroids and severity of symptoms. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that competitively inhibits pituitary gonadotropin-releasing hormone receptor activity and suppresses the release of gonadotropins from the pituitary gland, resulting in dose-depende

SUBMITTER: Al-Hendy A 

PROVIDER: S-EPMC8800453 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature